Biological platform: LYSA-BIO
In the future, lymphoma therapy will widely benefit from the huge amount of immunopathological knowledge gained in the past few years. In addition to the conventional cytotoxic agents, new therapeutic strategies will include therapies targeting tumour cells, as well as the cellular microenvironment involved in the genesis of lymphoma or its sensitivity to treatments.
LYSA decided to take care of the clinical trials’ biological aspects by setting up the biological platform (LYSA-BIO), which includes several experts on specific platforms. In this way, the questions pertaining to residual disease, tailored blood analyses, adaptation of immunological follow-up, as well as specific genetic analyses, can be addressed based on standardised protocols and according to validated techniques.